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The order and fidelity of cell cycle events in mammals is intimately linked to the integrity of the Chk1
kinase-Cdc25A phosphatase pathway. Chk1 phosphorylation targets Cdc25A for destruction and, as shown
here, inhibits interactions between Cdc25A and its mitotic substrate cyclin B1-Cdk1. Phosphorylation of
Cdc25A on serine 178 and threonine 507 facilitates 14-3-3 binding, and Chk1 phosphorylates both residues in
vitro. Mutation of T507 to alanine (T507A) enhanced the biological activity of Cdc25A. Cdc25A(T507A) was
more efficient in binding to cyclin B1, activating cyclin B1-Cdk1, and promoting premature entry into mitosis.
We propose that the Chk1/Cdc25A/14-3-3 pathway functions to prevent cells from entering into mitosis prior
to replicating their genomes to ensure the fidelity of the cell division process.
Human Cdc25A is phosphorylated at several sites in vivo,
and Chk1 is required for the majority of these phosphorylations in vivo during interphase (57). Chk1 phosphorylates
Cdc25A to promote its ubiquitin-mediated proteolysis (11, 16,
20, 46, 57). Chk1 also promotes the degradation of Cdc25A in
Xenopus laevis (26, 45). In vitro, Chk1 phosphorylates human
Cdc25A at several sites, and phosphorylation of these residues
requires Chk1 in vivo (46, 57). These findings argue that Chk1
is a major regulator of Cdc25A phosphorylation in vivo. Here
we identify additional Cdc25A phosphorylation sites and report a novel mechanism of Chk1-mediated Cdc25A regulation
involving 14-3-3 proteins.

The Cdc25A protein phosphatase positively regulates the
cell cycle by activating cyclin-dependent protein kinases
(Cdks). Cdc25A was identified as a potential human oncogene
based on its ability to transform primary mouse embryo fibroblasts in cooperation with activated Ras or loss of RB (14). In
addition, Cdc25A is overexpressed in a variety of human cancers (5, 6, 15, 34), and in many cases, Cdc25A overexpression
is a poor prognostic indicator. Cdc25A is an E2F target gene,
and Cdc25A is required for efficient induction of S-phase entry
by E2F-1 (47). Overexpression of Cdc25A accelerates S-phase
entry (4, 44), and microinjection of antibodies against Cdc25A
arrests cells in G1 (23, 25). Although these findings indicate an
important role for Cdc25A in regulating the G1-to-S phase
transition, Cdc25A also functions at other cell cycle stages (13,
30, 52, 57). Cdc25A is capable of binding to cyclins D1, E, A,
and B1 and can dephosphorylate Cdks bound to each of these
cyclins in vitro (13, 43, 52). In addition, Cdc25A is present and
active in all stages of the cell cycle and Cdc25A levels rise as
cells progress from G2 phase into mitosis (3, 4, 23, 25, 30, 31,
44).
The activity and abundance of Cdc25A is regulated by reversible phosphorylation, protein-protein interactions, and
ubiquitin-mediated proteolysis (3, 8, 23, 29, 31). Regulation of
Cdc25A is essential not only for progression of cells through an
unperturbed cell division cycle but also for cells to arrest in
response to checkpoint activation (57). Cdc25A is rapidly degraded in a proteasome-dependent manner in cells exposed to
UV light, hydroxyurea, or ionizing radiation (IR) (11, 29, 31).
In addition, overexpression of Cdc25A causes bypass of the
IR-induced S- and G2-phase checkpoints and the DNA replication checkpoint (11, 29–31).

MATERIALS AND METHODS
Antibodies. Cdc25A was detected with antibodies purchased from Santa Cruz
and Upstate Biotechnology, Inc. (UBI). Cdc25A fusion proteins were precipitated with anti-c-Myc (9E10)–agarose conjugate and detected by Western blotting with c-Myc polyclonal antibody (Santa Cruz). Anti-14-3-3, -cyclin B1, -Cdk1,
-glutathione S-transferase (GST), and -His antibodies, as well as anti-cyclin B1
conjugated to agarose, were purchased from Santa Cruz. Anti-phospho-histone
H3 antibodies were purchased from UBI, and ␤-catenin antibodies were purchased from Transduction Laboratories. Antibodies specific for Cdc25A phosphorylated at S178 and T507 were generated by immunizing rabbits with the
phosphopeptides C-TQRQNpSAPAR and C-RTKSRpTWAGE coupled to keyhole limpet hemocyanin.
Generation of tTA-regulated adenoviruses. An XhoI/HindIII fragment of
pUHD10-3 (17, 40), containing seven repeats of the tetracycline operator linked
to a cytomegalovirus minimal immediate-early promoter, a polylinker for cloning, and a simian virus 40 polyadenylation signal, was subcloned into pAdTrack
(21). The resulting plasmid (pAdTrackTRE) was digested with XbaI and ligated
to a linker containing SalI, NotI, EcoRV, and XhoI restriction sites to generate
pAdTrackTRE-SX. pAdTrackTRE-SX carrying the genes for Myc-tagged forms
of Cdc25A was cotransformed with pAdEasy-1 into Escherichia coli BJ5183 to
achieve homologous recombination. Recombinant adenoviruses were generated
and propagated in 293 cells using the pAdEasy system as described previously
(21). Expression of Cdc25A is regulated by the tetracycline transactivator (tTA),
with recombinant adenovirus encoding tTA (24).
14-3-3 binding assays. Transfected Cosm6 or 293 cells infected with recombinant adenoviruses were suspended in buffer A (10 mM Tris-HCl [pH 7.5], 5
mM MgCl2, 1 mM EGTA, 25 mM NaF) supplemented with 1 mM dithiothreitol
(DTT) and the following inhibitor cocktail: 1 M microcystin, 1 mM sodium
orthovanadate, 2 mM phenylmethylsulfonyl fluoride (PMSF), 0.15 U of aprotinin
per ml, 20 M leupeptin, and 20 M pepstatin. Cells were lysed by passage
through a 25-gauge needle 30 times. Precleared lysates were incubated with
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were collected 3 h after release (7 h of infection). Alternatively, HeLa cells were
transfected for 24 h with plasmid DNA encoding Myc-tagged versions of Cdc25A
using Lipofectamine 2000 (Invitrogen). Cells were lysed in buffer A supplemented with 1 mM DTT and inhibitor cocktail by passage through a 27-gauge
needle 30 times. Myc-Cdc25A proteins were precipitated using anti-cMyc(9E10)–agarose. Precipitates were resolved by SDS-PAGE followed by
Western blotting with anti-Myc or anti-cyclin B1 antibodies.
Purification of cyclin B1/Cdk1 complexes phosphorylated at T14 and Y15. Sf9
insect cells were coinfected with recombinant baculoviruses encoding Xenopus
Myt (32), GST-cyclin B1 (human), and human Cdk1 (1, 36). Xenopus Myt
efficiently phosphorylates Cdk1 on both threonine 14 and tyrosine 15. Cells were
collected 40 h later, washed in PBS, and then lysed for 15 min at 4°C in NETN
buffer (20 mM Tris-HCl [pH 8.0], 100 mM NaCl, 1 mM EDTA, 0.5% NP-40)
supplemented with 2 mM DTT, 1 M microcystin, 1 mM sodium orthovanadate,
2 mM PMSF, 0.15 U of aprotinin per ml, 20 M leupeptin, and 20 M pepstatin.
Clarified lysates were incubated with glutathione-agarose beads (Sigma Chemical Co.). Beads were washed four times with NETN, three times with LiCl buffer
(0.5 M LiCl, 50 mM Tris, pH 8.0), and three times with thrombin cleavage buffer
(TCB; 25 mM Tris [pH 7.5], 1 mM EDTA, 100 mM NaCl, 2.5 mM CaCl2, 0.01%
Brij 35). Cyclin B1/Cdk1 complexes were cleaved from GST and eluted from the
beads in TCB containing 30 mM glutathione and 50 U of thrombin in TCB for
1 h at room temperature. Supernatants were loaded on 2-ml Q Sepharose
columns (Pharmacia) that had been washed several times with buffer B (25 mM
Tris [pH 7.5], 1 mM EDTA, 0.01% Brij 35). Columns were washed with 10
volumes of buffer B, and complexes were eluted in buffer B containing 1 M NaCl.
Fractions containing phosphorylated Cdk1/cyclin B1 complexes were pooled,
dialyzed in a solution containing 20 mM Tris (pH 7.4), 2 mM DTT, and 10%
glycerin, and frozen at ⫺80°C.
Phosphatase assays using bacterial GST fusion proteins and Cdk1/cyclin B1
complexes. DH5␣ cells were transformed with plasmids encoding GST fusions of
Cdc25A (wt and mutants), cultures were grown at 37°C to an A600 of 0.6, and
isopropyl-1-thio-␤-D-galactopyranoside (IPTG) was added to a final concentration of 1 mM. After growing for an additional 2 h at 37°C, cells were pelleted by
centrifugation. Cell pellets were washed with PBS and then suspended in STE
(10 mM Tris-HCl [pH 8.0], 100 mM NaCl, 1 mM EDTA) containing 1.25%
N-lauryl sarcosine supplemented with 2 mM DTT, 1 mg of lysozyme per ml, and
proteinase inhibitors (4 mM PMSF, 20 g of aprotinin per ml, 40 M leupeptin).
After rocking at 4°C for 20 min, cells were lysed by sonication. Lysates were
clarified by centrifugation (13,000 ⫻ g for 15 min), and Triton X-100 was added
to a final concentration of 1%. Proteins were precipitated with GST-agarose
beads (Sigma Chemical Co.) and washed twice with NETN buffer, twice with
NETN buffer containing 1 M NaCl, and twice with phosphatase buffer (20 mM
Tris-HCl [pH 8.0], 2 mM EDTA, 2 mM DTT). The levels of GST fusion proteins
were estimated by comparison to a BSA standard after SDS-PAGE and Coomassie blue staining or were quantified by using GST antibodies, enhanced
chemifluorescence (ECF) reagents, and the Storm 860 imaging system (Amersham). Recombinant Cdc25A immobilized on 10 l of GST-agarose was suspended in 17 l of phosphatase buffer. Reactions were incubated at 30°C for 10,
15, or 20 min after the addition of 3 l of cyclin B1/Cdk1 substrate. Reactions
were stopped by the addition of 1 l of 50 mM sodium vanadate and were placed
on ice. Activation of cyclin B1/Cdk1 was determined by performing histone H1
kinase assays. Ten microliters of 4⫻ kinase buffer (80 mM Tris-HCl [pH 7.5], 60
mM MgCl2, 4 mM DTT, 0.8 mM ATP, 2 mg of histone H1 per ml, and 40 Ci
of [␥-32P]ATP) was added, and reactions were incubated at 30°C for 10 min.
Proteins were resolved by SDS-PAGE on a 12% acrylamide gel and then transferred to nitrocellulose. Radiolabeled histone H1 was excised, and radioactivity
was quantitated in a scintillation counter. The linearity of each assay was verified
by comparing counts obtained at each time point. Levels of Cdc25A in each
reaction were quantified using ECF reagents and the Storm 860 imaging system.
Histone H1 kinase activities were normalized for levels of Cdc25A in each
reaction.
Phosphatase assays using HeLa cell-derived Cdc25A and Cdk1/cyclin B1
complexes. Approximately 3 ⫻ 106 cells per 100-mm-diameter tissue culture dish
were coinfected with recombinant adenoviruses encoding Myc-tagged Cdc25A
(wt and mutants) and tTA at a multiplicity of infection of 5 for a total of 8 h. A
portion of the infected cells was harvested for FACS analysis to ensure that cell
cycle profiles were similar, and the remaining cells were suspended in buffer A
and lysed by passage through a 27-gauge needle 30 times. After centrifugation at
16,600 ⫻ g for 5 min, supernatants were further clarified by centrifugation at
100,000 ⫻ g for 1 h. Lysates were incubated with 25 l of packed protein
A-agarose (Pierce) at 4°C for 1 h. Cdc25A immunoprecipitations were performed with 20 l of anti-c-Myc(9E10)–agarose conjugate at 4°C for 2 h. Precipitates were washed four times in buffer A and twice with phosphatase buffer

Downloaded from http://mcb.asm.org/ on January 6, 2014 by Washington University in St. Louis

anti-c-Myc(9E10)–agarose, and Cdc25A precipitates were washed in buffer A.
Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed for Myc-Cdc25A and 14-3-3 proteins by
Western blotting.
Far-Western analysis. HeLa cells coinfected with recombinant adenoviruses
encoding tTA and Myc-tagged versions of wild-type (wt) and mutant Cdc25A
proteins were lysed in mammalian cell lysis buffer (MCLB; 50 mM Tris-HCl [pH
8.0], 150 mM NaCl, 0.5% NP-40, 5 mM EDTA, 2 mM DTT, 1 mM sodium
orthovanadate, 10 mM ␤-glycerophosphate, 1 mM NaF, 1 M microcystin, 1 mM
PMSF, 5 g of leupeptin per ml, and 10 g of aprotinin per ml). Clarified
supernatants were incubated with anti-c-Myc(9E10)–agarose conjugate. Precipitates were resolved by SDS-PAGE and transferred to Hybond-P membranes
(Amersham). Membranes were blocked in 5% milk–TBS (10 mM Tris [pH 8.0],
150 mM NaCl) overnight at 4°C and then washed in TBS. Washed membranes
were incubated in 0.1 g of GST–14-3-3ε per ml in 1-mg/ml bovine serum
albumin (BSA) in TBS. Membranes were washed in TBS and then incubated in
GST antibody. Membranes were washed in TBS and then incubated with horseradish peroxidase-conjugated anti-rabbit immunoglobulin G. Proteins were visualized by the ECL system (Amersham). Membranes were stripped and reprobed using anti-Myc antibodies to detect Myc-tagged Cdc25A. For peptide
competition assays, membranes were washed and blocked as described above.
Peptide (0.1 mM) was incubated with 0.1 g of GST–14-3-3ε per ml in TBS
containing 1 mg of BSA per ml for 2 h at room temperature. Membranes were
then incubated in the peptide–GST–14-3-3ε mixture overnight at 4°C. Membranes were washed in TBS, incubated with antibodies specific for GST, and
processed as described above. The peptides used for the competition assays were
as follows: PHCVPRDLSWLDLEANMCLP (38, 48) and phosphorylated and
unphosphorylated forms of C-TQRQNS178APAR and C-RTKSRT507WAGE. In
addition, two phosphopeptides lacking 14-3-3 consensus sequences were used. The
pT68 phosphopeptide from Chk2 consists of the sequence C-ETVSpT68QELYS,
and the pS123 phosphopeptide from Cdc25A consists of the sequence CLKRSHpS123DSLD.
siRNA experiments. The small interfering RNA (siRNA) oligonucleotide corresponding to nucleotides 127 to 147 of the human Chk1 coding region (57) was
synthesized by Dharmacon Research, Inc. The control siRNA duplex was designed based on a target sequence of 5⬘-GCGCGCTTTGTAGGATTCG-3⬘.
siRNA duplexes were transfected into HeLa cells using Oligofectamine (Invitrogen) according to the manufacturer’s recommendations. Twenty-four hours after
transfection, cells were coinfected with adenoviruses encoding tTA and Myctagged versions of wt and mutant Cdc25A proteins. Cells were harvested 9 h after
infection by lysing in MCLB. Proteins were resolved by SDS-PAGE and analyzed
by Western blotting.
Double thymidine block and release protocol. To synchronize HeLa cells at
the G1/S border, cells were treated with 2 mM thymidine for 16 to 19 h. Cells
were released from the block by washing with phosphate-buffered saline (PBS),
followed by trypsinization and reseeding into complete growth medium containing 24 M (each) thymidine and 2⬘-deoxycytidine. After 8 to 9 h, thymidine was
added to the medium to a final concentration of 2 mM, and cells were cultured
for an additional 16 to 18 h. Cells were then rinsed twice with PBS and cultured
in complete growth medium.
Overproduction of Cdc25A proteins in S phase. HeLa cells were synchronized
using a double thymidine block and release protocol. Four hours before release
from the second block, cells were coinfected with adenoviruses encoding tTA
and GFP (control) or tTA and Myc-tagged versions of wt and mutant Cdc25A
proteins. Infections were carried out at a multiplicity of infection of 5 to 10. Cells
were harvested by trypsinization 3 h after release from the second block. A
portion of the cells was analyzed for chromosomal integrity by performing chromosome spreads (22) and for percent mitotic cells by costaining with propidium
iodide (PI) and anti-phospho-histone H3 antibody (50). Cell cycle profiles were
obtained by fluorescence-activated cell sorting (FACS) using a FACSCaliber
machine (Becton-Dickinson Instruments). The data were analyzed with Cellquest software (Becton-Dickinson). The remaining cells were lysed in MCLB and
analyzed for Cdc25A by Western blotting or were incubated with anti-cyclin B1
agarose. Cyclin B1/Cdk1 precipitates were washed in incomplete kinase buffer
(20 mM Tris-HCl [pH 7.5], 15 mM MgCl2, 1 mM DTT), and kinase reactions
were carried out in buffer consisting of 20 mM Tris-HCl (pH 7.5), 15 mM MgCl2,
1 mM DTT, 0.5 mg of histone H1 per ml, 0.2 mM ATP, and 10 Ci of [32P]ATP.
Proteins were resolved by SDS-PAGE and transferred onto nitrocellulose. Radiolabeled histone H1 was visualized by autoradiography and quantitated by
scintillation counting.
Cyclin B1 binding assays. HeLa cells were synchronized using a double thymidine block. Four hours prior to release, cells were coinfected with adenoviruses encoding tTA and GFP or tTA and wt or mutant Cdc25A. Infected cells
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and then were suspended in 75 l of phosphatase buffer. Five microliters of
Cdc25A immobilized on Myc-agarose was suspended in 20 l of phosphatase
buffer. Reactions were incubated at 30°C for 10, 15, or 20 min after the addition
of 5 l of cyclin B1/Cdk1 substrate. Samples were processed for histone H1
kinase assays as described above. The remaining Cdc25A precipitates were
immunoblotted and quantified by using Myc antibodies, ECF reagents, and the
Storm 860 imaging system. Histone H1 kinase activities were normalized for
levels of Cdc25A in each reaction.
Phosphatase assays using mFP. The levels of GST fusion proteins were
estimated by comparison to a BSA standard after SDS-PAGE and Coomassie
blue staining or were quantified by using ECF reagents and the Storm 860
imaging system. Immunoblotting was performed with antibody specific for GST
together with alkaline phosphatase (AP)-conjugated anti-rabbit immunoglobulin
G (Jackson ImmunoResearch). Proteins were visualized by chemifluorescence.
Approximately 10 g of purified GST-Cdc25A (wt and mutants) was incubated
in 500 l of buffer consisting of 50 mM Tris, 50 mM Bis-Tris, 100 mM sodium
acetate (pH 6.5), 0.01% Tween 20, 1 mM DTT, and 62.5 M 3-O-methyl
fluorescein phosphate (mFP) (Sigma) at room temperature as described previously (49). Reactions were followed by spectroscopy at 477 nm. All experiments
were done in triplicate.
Phosphorylation of S178 and T507 as a function of the cell cycle. HeLa cells
synchronized by a double thymidine block were infected with adenoviruses encoding Myc-tagged Cdc25A and tTA. G1/S-arrested cells were collected prior to
release from the second block, S-phase cells were collected at 3 h after release
from the block, and G2-phase cells were collected 7 h after release from the

block. Mitotic cells were obtained by infecting cells immediately after release
from the block in medium containing nocodazole for 10 h.
Additional methods. Cdc25A mutants were generated by a PCR-based strategy or by use of the QuickChange XL site-directed mutagenesis kit (Stratagene)
and were verified by sequencing.
Chk1 and Chk2 kinase reactions were carried out in vitro with bacterially
produced His-Cdc25A and insect cell-produced GST-tagged Chk1 and Chk2 as
described previously (19, 57).

RESULTS
Phosphorylation of Cdc25A at S178 and T507 mediates the
binding of 14-3-3 proteins to Cdc25A. 14-3-3 proteins were
isolated in a two-hybrid screen using human Cdc25A as bait
(8). A mutagenesis strategy was employed to identify residues
in Cdc25A that confer 14-3-3 binding (Fig. 1A). 14-3-3 bound
independently to both the N (amino acids 1 to 336) and C
(amino acids 389 to 524) termini of Cdc25A. Substitution of
alanine for serine 178 (S178A) eliminated binding to residues
1 to 336 and substitution of alanine for threonine 507 (T507A)
eliminated 14-3-3 binding to residues 389 to 524. Full-length
Cdc25A proteins substituting alanine for S178, T507, or both
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FIG. 1. Dependency of 14-3-3 binding to Cdc25A on S178 and T507. (A) Cosm6 cells transfected with vector alone (mock) or with plasmids
encoding the indicated forms of Myc-Cdc25A were lysed and incubated with anti-c-Myc–agarose. Precipitates were resolved by SDS-PAGE and
monitored for Cdc25A and 14-3-3 proteins by immunoblotting. ⫹, coprecipitation of 14-3-3 with Cdc25A; ⫺, absence of 14-3-3 in Cdc25A
precipitates. (B) 293 cells mock infected or infected with recombinant adenovirus encoding the indicated forms of Cdc25A were lysed and then
incubated with anti-c-Myc–agarose. Precipitates were resolved by SDS-PAGE and monitored for Cdc25A and 14-3-3 proteins by immunoblotting.
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were generated and tested for 14-3-3 binding. Complete loss of
14-3-3 binding was seen when both S178 and T507 were replaced with alanine (Fig. 1B, lane 5). Thus, both S178 and T507
are required for interactions between Cdc25A and 14-3-3 proteins. The phosphatase activity of Cdc25A was not absolutely
required for 14-3-3 binding, as a catalytically inactive form of
Cdc25A (C430S) was capable of binding to 14-3-3 proteins
(Fig. 1B, lane 6).
14-3-3 binding to target proteins is, in general, mediated by
phosphorylation (33, 54). Phosphorylation of Cdc25A at S178
and T507 in vivo was confirmed using phospho-specific antibodies (Fig. 2A). In addition, mutation of S178 did not affect
phosphorylation of T507 nor did mutation of T507 affect phosphorylation of S178. Given that phosphorylation of Cdc25A in
vivo is absolutely dependent on Chk1, we predicted that Chk1
would phosphorylate Cdc25A at S178 and T507 in vitro (57).
As seen in Fig. 2B, Chk1 phosphorylated both residues in vitro
(lanes 1 to 3). Interestingly, the Chk2 protein kinase, which has
been proposed to regulate Cdc25A following IR (11), was
incapable of phosphorylating Cdc25A at T507 in vitro (Fig. 2B,

lanes 4 to 6). Next, the phosphorylation of Cdc25A at T507 and
S178 was examined in cells in which Chk1 levels had been
reduced by Chk1-specific siRNAs. As seen in Fig. 2C, Chk1 but
not ␤-catenin levels were significantly reduced in cells treated
with Chk1-specific siRNAs (lanes 2 and 4). Levels of both
Cdc25A (lane 2) and Cdc25A(S178A/T507A) (lane 4) were
higher in cells in which Chk1 levels had been reduced by
siRNA treatment. This result is consistent with our previous
work demonstrating that Chk1 negatively regulates the stability
of Cdc25A during an unperturbed cell cycle (57). Importantly,
even though Cdc25A levels were elevated in cells lacking Chk1,
reactivity of Cdc25A with the pT507 antibody was significantly
reduced (lane 2) relative to reactivity of Cdc25A in cells containing Chk1 (lane 1). Loss of Chk1 did not affect S178 phosphorylation as dramatically as T507 phosphorylation. These
results support the conclusion that Chk1 is the major T507
kinase but that kinases in addition to Chk1 regulate S178
phosphorylation. This is consistent with the results in Fig. 2B
showing that Chk2 is capable of phosphorylating Cdc25A at
S178 but not T507 in vitro.
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FIG. 2. Phosphorylation of Cdc25A at S178 and T507 in vivo and in vitro. (A) Lysates from HeLa cells infected with adenoviruses encoding
the indicated Myc-Cdc25A proteins were resolved by SDS-PAGE, and proteins were detected by immunoblotting with phospho-specific antibodies
followed by antibodies specific for the Myc epitope (anti-Myc). (B) Kinase assays were performed in vitro in the presence of His6Cdc25A proteins
and either GST-Chk1 or GST-Chk2. Reaction products were resolved by SDS-PAGE and subjected to Western blotting to monitor phosphorylation of Cdc25A at T507 (anti-pT507) and S178 (anti-pS178) and to monitor levels of His6Cdc25A (anti-His), GST-Chk1, and GST-Chk2
(anti-GST). (C) HeLa cells were treated with control or Chk1-specific siRNAs followed by infection with recombinant adenovirus encoding the
indicated forms of Cdc25A. Lysates were prepared and analyzed by Western blotting with the indicated antibodies.
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Far Western analysis was performed to determine if binding
of 14-3-3 to Cdc25A was direct. As seen in Fig. 3A, 14-3-3
bound directly to Cdc25A (lane 1) but poorly to the S178A
(lane 2) and S178A/T507A (lane 4) mutants. Furthermore,
peptides containing phosphorylated S178 (Fig. 3B, lane 4) or
T507 (Fig. 3B, lane 6, and Fig. 3C, lane 3) competed for 14-3-3
binding, as did an unphosphorylated peptide (Fig. 3B and C,
lanes 2) that binds to 14-3-3 proteins (38, 48). The unphosphorylated S178 and T507 peptides did not compete efficiently
in this assay, nor did phosphopeptides lacking 14-3-3 consensus
motifs (Fig. 3C). These results demonstrate that 14-3-3 binds
directly to Cdc25A and that phosphorylation of S178 and T507
mediates this interaction.
14-3-3 binding mutants induce a mitotic-like state in Sphase cells. A high percentage of abnormal chromosome
spreads were observed in S-phase cells expressing the T507A
or S178A/T507A mutant (Fig. 4B and C). In addition, cyclin
B1-associated kinase activity was approximately threefold
higher in cells expressing Cdc25A(T507A) or Cdc25A(S178A/
T507A) than in cells expressing wt Cdc25A, and the activity
was approximately 1.5-fold higher in cells expressing Cdc25A
(S178A) (Fig. 4D). Furthermore, S-phase cells expressing the
T507A or S178A/T507A mutant stained positive for histone
H3 phosphorylation, a modification normally seen only in mitotic cells (Fig. 5) (50, 51). PI staining confirmed that cells were
in S phase. Approximately 8 to 9% of cells expressing wt

FIG. 4. 14-3-3 binding mutants activate cyclin B1/Cdk1 and induce
a mitotic-like state when expressed in S phase. S-phase HeLa cells
expressing GFP and various forms of Myc-Cdc25A were analyzed for
Cdc25A levels by Western blotting (A) and for chromosomal integrity
by examining DAPI-stained nuclei (B and C). Magnification, ⫻40
(B) and ⫻100 (C). Cells were also analyzed for cyclin B1-associated
histone H1 kinase activity (D). Standard errors of the means (n ⫽ 4)
are shown as error bars along the y axis.

Cdc25A or Cdc25A(S178A) stained positive for phospho-histone H3, whereas the percentage staining positive for phosphohistone H3 increased significantly in cells expressing the
T507A (29.1%) or S178A/T507A (28.0%) mutant. Failure to
observe cells with DNA contents of less than 2N indicates that
the 14-3-3 binding mutants did not induce S-phase cells to
undergo apoptosis.
Phosphorylation of Cdc25A on T507 negatively regulates the
ability of Cdc25A to dephosphorylate Cdk1. Phosphatase assays were performed to monitor the ability of each Cdc25A
mutant to dephosphorylate and activate cyclin B1/Cdk1 in
vitro. To verify that mutation of S178 and/or T507 did not
affect the intrinsic phosphatase activity of Cdc25A, the activity
of bacterially produced Cdc25A was examined, because bacterial Cdc25A is neither phosphorylated nor bound to 14-3-3
proteins. Mutation of S178 and T507 either alone or together
did not affect the activity of bacterially produced Cdc25A (Fig.
6A). Next, HeLa cells were infected with adenoviruses encod-
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FIG. 3. Interactions between Cdc25A and 14-3-3 proteins are direct. (A) Far Western analysis was performed to monitor the binding
of 14-3-3 protein to wt and mutant forms of Cdc25A. Membranes
containing the indicated form of Myc-Cdc25A were incubated with
purified GST–14-3-3ε, and 14-3-3 bound to Cdc25A was detected by
Western blotting with GST antibodies. (B and C) Specific phosphopeptides compete with 14-3-3 proteins for binding to Cdc25A.
Membranes containing the indicated forms of Myc-Cdc25A were incubated with GST–14-3-3ε in the presence of the indicated phosphoand nonphosphopeptides. 14-3-3 bound to Cdc25A was detected by
Western blotting with GST antibodies.
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ing GFP, Cdc25A, or mutant forms of Cdc25A. Cells were
subjected to FACS analysis at the time of harvest to verify that
cell cycle profiles were identical (data not shown). wt and
mutant forms of Cdc25A were isolated from infected cells and
assayed for the ability to activate Cdk1 in vitro. HeLa cellderived Cdc25A, unlike bacterially derived protein, is phosphorylated and bound to 14-3-3 proteins. The T507A and
S178A/T507A mutants consistently showed an approximately
twofold increase relative to wt Cdc25A in the ability to activate
cyclin B1/Cdk1 in vitro (Fig. 6B). The activity of
Cdc25A(S178A) was modestly increased over that of wt
Cdc25A. Furthermore, higher levels of cyclin B1/Cdk1 were
observed to coprecipitate with the 14-3-3 binding mutants of
Cdc25A than with wt Cdc25A (Fig. 7B).
The C terminus of Cdc25A contains a cyclin B1/Cdk1 docking site. Taken together, these results suggest that phosphorylation of T507 and subsequent 14-3-3 binding to the C terminus of Cdc25A negatively regulates interactions between
Cdc25A and cyclin B1/Cdk1. Cdc25B has a cyclin/Cdk docking
site within its C terminus (49), and Cdc25A, but not Cdc25C,
conserves many of these residues (Fig. 7A). To test whether
the C terminus of Cdc25A conferred cyclin B1/Cdk1 binding,
mutations in the putative binding domain were generated and
mutants were tested for the ability to bind to cyclin B1/Cdk1
(Fig. 7C). Mutation of K514 and R520 severely impaired the
ability of Cdc25A to bind to cyclin B1/Cdk1.
If the T507A and S178A/T507A mutants obtain their biological potency by enhanced binding to cyclin B1/Cdk1, mutation of residues in the binding domain is expected to reduce
this potency. To test this, S-phase cells expressing wt and mu-

FIG. 6. Threonine 507 negatively regulates phosphatase activity of
Cdc25A. wt and mutant forms of Cdc25A were purified as GST fusion
proteins from bacteria (A) or as Myc fusion proteins from HeLa cells
(B). Phosphatase assays were carried out in the presence of Cdc25A
and purified cyclin B1/Cdk1 containing Cdk1 phosphorylated on both
T14 and Y15. Phosphatase reactions were terminated and histone H1
kinase assays were performed to measure the activation of cyclin B1/
Cdk1. 32P incorporation into histone H1 was determined by scintillation counting. Cdc25A precipitates were immunoblotted and quantified by use of Myc antibodies, ECF reagents, and the Storm 860
imaging system (Amersham). Histone H1 kinase activities were normalized for levels of Cdc25A in each reaction. Values obtained for wt
Cdc25A were set at 100, and the mutant values are shown relative to
this. Standard errors of the means (n ⱖ 3) are shown as error bars
along the y axis.

tant forms of Cdc25A were monitored for cyclin B1/Cdk1associated histone H1 kinase activity. As seen in Fig. 4D, the
binding domain mutants of Cdc25A exhibited reduced capacities to activate cyclin B1/Cdk1 in vivo. To verify that the
binding domain mutants retained phosphatase activity, their
ability to dephosphorylate the artificial substrate mFP in vitro
was tested (49). As seen in Fig. 7E, mutation of the binding
domain did not affect the intrinsic activity of Cdc25A toward
mFP.
Interactions between Cdc25A and 14-3-3 proteins are cell
cycle regulated. These results suggest that phosphorylation of
Cdc25A on T507 and subsequent 14-3-3 binding prevent
Cdc25A from binding to cyclin B1/Cdk1. This model predicts
that Cdc25A should be phosphorylated on T507 and bound to
14-3-3 proteins until cells approach mitosis, at which point loss
of 14-3-3 binding would promote activation of the Cdk1 kinase.

Downloaded from http://mcb.asm.org/ on January 6, 2014 by Washington University in St. Louis

FIG. 5. 14-3-3 binding mutants induce histone H3 phosphorylation
in S-phase cells. S-phase HeLa cells expressing GFP and various forms
of Myc-Cdc25A (same cells as for Fig. 4) were costained for DNA
content and histone H3 phosphorylation and analyzed by flow cytometry (50). Percentages of mitotic cells are indicated.
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To test this, phospho-specific antibodies were used to examine
the phosphorylation of Cdc25A on S178 and T507 throughout
the cell cycle. Because of its low abundance and short half-life,
we were unable to monitor the binding of endogenous Cdc25A
to 14-3-3 proteins in vivo. Therefore, cells at various stages of
the cell cycle were infected with recombinant adenovirus that
inducibly expresses Cdc25A, and phosphorylation of S178 and
T507 was monitored using phospho-specific antibodies (Fig. 8).
The phosphorylation of Cdc25A at S178 and T507 appeared
constant throughout the G1 and S phases of the cell cycle.
Despite elevated levels of Cdc25A in the G2 and M phases of
the cell cycle, reactivity with the phospho-specific antibodies

(particularly pT507) was observed to decrease (Fig. 8C, lanes 4
and 5).
DISCUSSION
In this study, a new function for the Chk1 protein kinase in
regulating mitotic entry is proposed (Fig. 9). We demonstrate
that Chk1 phosphorylates Cdc25A at S178 and T507 in vitro
and that phosphorylation of these residues mediates binding of
14-3-3 protein to Cdc25A in vivo. Because phosphorylation of
Cdc25A in vivo is absolutely dependent on Chk1 (57) and
because Chk1 phosphorylates Cdc25A at S178 and T507 in
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FIG. 7. The C terminus of Cdc25A contains a cyclin B1 docking site. (A) Schematic representation of Cdc25A and amino acids comprising the
C-terminal cyclin B1 docking site. Asterisks denote K514 and R520. (B) Loss of 14-3-3 binding promotes interactions between Cdc25A and cyclin
B1. HeLa cells synchronized at the G1/S border were infected with recombinant adenoviruses encoding GFP (control) or with recombinant viruses
encoding various forms of Myc-Cdc25A. Three hours after release from the block, S-phase cells were lysed and incubated with anti-c-Myc–agarose.
Myc-Cdc25A precipitates were resolved by SDS-PAGE, and Cdc25A and cyclin B1 were visualized by immunoblotting. (C) The C terminus of
Cdc25A is required for interactions between Cdc25A and cyclin B1. HeLa cells synchronized at the G1/S border were infected with recombinant
adenoviruses encoding GFP (control) or with recombinant viruses encoding various forms of Myc-Cdc25A. Three hours after release from the
block, S-phase cells were lysed and incubated with anti-c-Myc–agarose. Myc-Cdc25A precipitates were resolved by SDS-PAGE, and Cdc25A and
cyclin B1 were visualized by immunoblotting. (D and E) Mutation of the cyclin B1 docking site does not impair phosphatase activity of Cdc25A.
wt and mutant forms of Cdc25A were purified from bacteria as GST fusion proteins, resolved by SDS-PAGE, and visualized by Western blotting
(D). Purified proteins were tested for the ability to dephosphorylate mFP in vitro (E). Reactions were done in triplicate and followed by
spectroscopy at 477 nm. Standard errors of the means are shown as error bars along the y axis.
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FIG. 8. Phosphorylation of Cdc25A at S178 and T507 is cell cycle
regulated. HeLa cells expressing Myc-Cdc25A were synchronized at
the G1/S border by a double thymidine block protocol. Cells at the
G1/S border were collected prior to release from the block, and S- and
G2/M-phase cells were harvested at 3 and 7 h after release, respectively. Mitotic cells were obtained by incubation in nocodazole for 10 h
after infection and release. Some cells were harvested and analyzed by
FACS to determine DNA content (A). The remaining cells were lysed
and incubated with anti-c-Myc–agarose. Precipitates were resolved by
SDS-PAGE and incubated with phospho-specific antibodies followed
by antibodies specific for the Myc epitope to monitor Cdc25A levels (B
and C).

vitro (Fig. 2B), we infer that Chk1 regulates S178 and T507
phosphorylation in vivo. This conclusion is supported by the
finding that phosphorylation of T507 and, to a lesser extent,
S178 was impaired in Chk1-deficient cells (Fig. 2C). Thus,
Chk1 negatively regulates entry into mitosis by preventing
functional interactions between Cdc25A and the mitotic inducer Cdk1. Sorenson et al. (46) reported that both Chk1 and
Chk2 phosphorylate Cdc25A to promote its turnover. Here we
show that Chk1, but not Chk2, phosphorylates Cdc25A at T507
to prevent cyclin B1/Cdk1 binding. Thus, this study uncovers a
unique role for Chk1 in the negative regulation of Cdc25A.
In general, the binding of 14-3-3 proteins to their targets is
mediated by the phosphorylation of the target protein at one of
two 14-3-3-binding consensus motifs. These motifs include the
RSXpSXP (mode 1) and RX(Y/F)XpSXP (mode 2) sequences, where pS denotes either phosphoserine or phosphothreonine (33, 54). Given that each monomer of the 14-3-3
dimer can simultaneously bind distinct phosphoepitopes on a
single protein (35), it is possible that a single 14-3-3 dimer
simultaneously binds to pS178 and pT507 on a single Cdc25A
molecule. The sequences surrounding and inclusive of S178

(RQNpSAP) fit nicely with the mode 1 consensus, whereas
sequences inclusive of and surrounding T507 (TKSRpTWA)
do not fit either consensus very well. Thus, it is predicted that
S178 is a higher-affinity 14-3-3 binding site and could serve a
gatekeeper function, thereby increasing the affinity of 14-3-3
binding to the C terminus of Cdc25A when T507 is phosphorylated (53). In support of S178 serving a gatekeeper function,
mutation of S178 to alanine impaired the interactions between
Cdc25A and 14-3-3 to a much greater extent than did mutation
of T507 (Fig. 1B and 3A). However, pT507 must be able to
bind 14-3-3 independently of pS178, as the phenotype observed in cells expressing the S178 mutant was much less severe than that observed in cells expressing the T507 mutant.
T507 is located within a cyclin B1/Cdk1 docking site in the C
terminus of Cdc25A, and 14-3-3 binding to this region appears
to block Cdc25A from functionally interacting with cyclin B1/
Cdk1. Sequences comprising the cyclin B1/Cdk1 docking domain are highly conserved among vertebrate Cdc25 homologues, particularly Cdc25A and Cdc25B family members (39,
49), and this region is disordered in the crystal structures of
both Cdc25A and Cdc25B (12, 41). A motif within the N
terminus of Cdc25A confers binding of Cdc25A to Cdk complexes containing cyclins A and E but not B1 (43). Mutation of
this domain reduced binding of Cdc25A to cyclin A and E
complexes but not to cyclin B1/Cdk1. Thus, domains within the
N and C termini of Cdc25A are important for facilitating
interactions between Cdc25A and various cyclin/Cdks, but the
C-terminal domain appears to be the major determinant for
cyclin B1/Cdk1 binding.
Taken together, these data suggest that phosphorylation of
Cdc25A on T507 and subsequent 14-3-3 binding impair the
ability of Cdc25A to interact with cyclin B1/Cdk1. Cdc25A is
phosphorylated on T507 during the G1 and S phases of the cell
cycle, and reduced phosphorylation of T507 was noted during
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FIG. 9. Regulation of Cdc25A by Chk1. Chk1 phosphorylates
Cdc25A on several N-terminal serines to promote its ubiquitin-mediated proteolysis (11, 16, 20, 46, 57). Chk1 also phosphorylates Cdc25A
on S178 and T507 to facilitate 14-3-3 binding. 14-3-3 binding to the
C-terminal cyclin B1 binding domain (BD) of Cdc25A blocks functional interactions between Cdc25A and cyclin B1/Cdk1 throughout
interphase. These regulatory pathways prevent cells from entering into
mitosis at inappropriate times during the cell cycle and following
checkpoint activation. Solid arrows originating from Chk1 indicate
phosphorylation sites that mediate 14-3-3 binding, whereas hatched
lines represent sites that mediate Cdc25A turnover. S178 is the primary 14-3-3 binding site and S75 is the primary site regulating Cdc25A
turnover, as indicated by thicker arrows.
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